Our data report elevation of 2-AGP in CSF and plasma of AD patients in agreement with recent findings that indicate the failure of cognitive improvement after JZL-195 pharmacological inhibition of MAGL and FAAH activities in mouse model of AD (Bajaj et al., 2022). This evidence concerns the gene MGLL and Alzheimer disease.